Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Chemomab Therapeutics ( (CMMB) ) has provided an announcement.
On May 14, 2026, Chemomab reported first-quarter 2026 results and a corporate update centered on new clinical and translational data for nebokitug in primary sclerosing cholangitis. The company highlighted recent and upcoming presentations at Digestive Disease Week 2026 and the EASL 2026 Congress showing nebokitug’s impact on key fibrosis, liver biology, and immune activation markers in PSC patients, including those with concomitant inflammatory bowel disease.
New analyses from the Phase 2 SPRING trial used AI-driven proteomic profiling and gene expression program mapping to demonstrate dose-dependent improvements in composite fibrosis endpoints and down-regulation of core fibrotic and immune pathways tied to PSC progression. Additional biomarker data indicated that CCL24 inhibition by nebokitug modulates shared gut–liver inflammatory and tissue-remodeling signatures relevant to PSC-IBD co-morbidity, supporting Chemomab’s efforts to advance partnering discussions and potentially strengthen its position in the niche market for PSC and related inflammatory disorders.
The most recent analyst rating on (CMMB) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.
Spark’s Take on CMMB Stock
According to Spark, TipRanks’ AI Analyst, CMMB is a Neutral.
The score is primarily constrained by weak financial fundamentals (pre-revenue, ongoing losses, and negative free cash flow) and a technically weak price trend below major moving averages. Valuation contributes limited support due to the negative P/E and lack of dividend yield data.
To see Spark’s full report on CMMB stock, click here.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, focused on developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical need. Its lead candidate, nebokitug, targets the CCL24 pathway and is being developed as a potential first-in-class, disease-modifying treatment for primary sclerosing cholangitis and related gut–liver inflammatory conditions.
Average Trading Volume: 66,281
Technical Sentiment Signal: Sell
Current Market Cap: $12.73M
Find detailed analytics on CMMB stock on TipRanks’ Stock Analysis page.